İLKNUR ERDEM, Mustafa DOĞAN, Rıdvan KARAALİ, Şenay ELBASAN OMAR, Enes ARDİÇ

İNVAZİV ASPERGİLLOZ TEDAVİSİ

İnvaziv aspergilloz (İA), Aspergillus türü mantarların neden olduğu genellikle immünyetmezlikli hastalarda görülen ve yüksek mortalite ile seyreden bir enfeksiyon hastalığıdır. En sık akciğer etkilenmekle birlikte mantar vücudun diğer organlarına da yayılarak hastalık yapabilir. Tedavisinde halen vorikonazol birinci seçenek antifungaldir. Vorikonazol alamayacak ya da vorikonazole cevap vermeyen hastalarda tedavide alternatif olarak isavukonazol, itrakonazol, amfoterisin B lipid formülasyonu, itrakonazol, kaspofungin, mikafungin ve posakonazol kullanılabilir. Bu yazıda invaziv aspergilloz tedavisi gözden geçirilmiştir.

TREATMENT OF INVASIVE ASPERGILLOSIS

Invasive aspergillosis (IA) is an infectious disease caused by Aspergillus species, is usually seen in patients with immune deficiency and has been associated with high mortality rate. IA most commonly affects the lungs, but Aspergillus can also spread throughout the body and cause infection in other organs. Voriconazole is the firstline antifungal agent in the treatment of invasive aspergillosis. Other antifungal agents including isavuconazole, lipid amphotericin formulations, itraconazole, caspofungin, micafungin, and posaconazole can be used to treat IA in patients who can not take voriconazole or who have not responded to voriconazole. In this article, the treatment of invasive aspergillosis was reviewed.

PDF

___

Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327-60.
Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW et al. Practice guidelines for diseases caused by aspergillus. Clin Infect Dis. 2000;30(4):696-709.
Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R et al. Executive summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):433-42.
Karthaus M. Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin – Review of the literature. Eur J Med Res. 2011;16(4):145-52.
Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Croaert F et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34(1):7– 14.
Buchheidt D, Reinwald M, Hofmann WK, Boch T, Spiess B. Evaluating the use of PCR for diagnosing invasive aspergillosis. Expert Rev Mol Diagn. 2017;17(6):603-10.
Traunmüller F, Popovic M, Konz KH, Smolle-Jüttner FM, Joukhadar C. Efficacy and safety of current drug therapies for invasive aspergillosis. Pharmacology. 2011;88(3-4):213–24.
Steinbach WJ, Benjamin DK Jr, Kontoyiannis DP, Perfect JR, Lutsar I, Marr KA et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis. 2004;39(2):192– 8.
Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408-15.
Scholz I, Oberwittler H, Riedel KD, Burhenne J, Weiss J, Haefeli WE, Mikus G. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009;68(6):906–15.
Borys M, Piwowarczyk P, Sysiak J, Czuczwar M, Prystupa A. Early diagnosis and treatment of invasive aspergillosis as a main determinant of outcomereview of literature according to the presented case report. Ann Agric Environ Med. 2017;24(1):100-03.
Cornely OA, Böhme A, Buchheidt D, Ruhnke M, Cornely OA, Egerer G et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica. 2009;94(1):113-22.
Cesar JMS, Resende JS, Amaral NF, Alves CMS, Vilhena AF, Silva FL. Cavernostomy x Resection for pulmonary aspergilloma: A 32-year history. J Cardiothorac Surg. 2011;6:129.
Chen J, Chang Y, Luh S, Lee J, Lee Y. Surgical treatment for pulmonary aspergilloma: a 28 year experience. Thorax. 1997;52(9):810–3.
Shah A, Panjabi C. Allergic bronchopulmonary aspergillosis: a perplexing clinical entity Allergy Asthma Immunol Res. 2016;8(4):282-97.
Agarwal R, Chakrabarti A, Shah A, Gupta D, Meis JF, Guleria R, Moss R, Denning DW, ABFA complicating asthma ISHAM working group. Allergic bronchopulmonary aspergillosis: review of literature and proposal of a new diagnostic and classification criteria. Clin Exp Allergy. 2013;43(8):850-73.
Agarwal R, Khan A, Garg M, Aggarwal AN, Gupta D. Chest radiographic and computed tomographic manifestations in allergic bronchopulmonary aspergillosis. World J Radiol. 2012; 4(4):141-50.
Wark PA, Hensley MJ, Saltos N, Boyle MJ, Toneguzzi RC, Epid GD et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol. 2003;111(5):952–7.
Fernandez IJ, Stanzani M, Tolomelli G, Pasquini E, Vianelli N, Baccarani M, Sciarretta V. Sinonasal risk factors for the development of invasive fungal sinusitis in hematological patients: Are they important? Allergy Rhinol.(Providence). 2011;2(1):6–11.
Mohindra S, Mohindra S, Bal A. Allergic fungal sinusitis: innocence under suspicion. Med Mycol. 2012;50(2):179-86.
Schubert MS. Allergic fungal sinusitis: pathophysiology, diagnosis and management. Med Mycol. 2009;47:324-30.
Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant. 2003; 22(3):258–66.
Krenke R, Grabczak EM. Tracheobronchial manifestations of aspergillus infections. ScientificWorldJournal. 2011;11:2310-29.
Borro JM, Solé A, de la Torre M, Pastor A, Fernandez R, Saura A et al. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc. 2008;40:3090-3.
Alexander BD, Dodds Ashley ES, Addison RM, Alspaugh JA, Chao NJ, Perfect JR. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2006; 8(1):13–20.
Menasalvas A, Bouza E. Infective endocarditis caused by unusual organisms. Rev Esp Cardiol. 1998;51(2):79-85.
Pierrotti LC, Baddour LM. Fungal endocarditis, 1995– 2000. Chest. 2002; 122(1):302-10.
Pasha AK, Lee JZ, Low SW, Desai H, Lee KS, Al Mohajer M. Fungal Endocarditis: Update on diagnosis and management. Am J Med. 2016;129(10):1037-43.
Kalokhe AS, Rouphael N, El Chami MF, Workowski KA, Ganesh G, Jacob JT. Aspergillus endocarditis: a review of the literatüre. Int J Infect Dis. 2010;14(2):1040-7.
Kothari A, Pillai BS, Bhan A. Pacing lead endocarditis due to Aspergillus fumigatus. Indian J Med Microbiol. 2010;28(1):72-3.
Torre-Cisneros J, Lopez OL, Kusne S, Martinez AJ, Starzl TE, Simmons RL, Martin M. CNS aspergillosis in organ transplantation: a clinicopathological study. J Neurol Neurosurg Psychiatry. 1993;56(2):188-93.
Lin SJ, Schranz J, Teutsch SM. Aspergillosis casefatality rate: systematic review of the literatüre. Clin Infect Dis. 2001;32(3):358-66.
Koehler P, Tacke D, Cornely OA. Aspergillosis of bones and joints- a review from 2002 until today. Mycoses. 2014;57(6):323-35.
Paterson DL. New clinical presentations of invasive aspergillosis in non-conventional hosts. Clin Microbiol Infec Dis. 2004;10:24-30.
Dotis J, Roilides E. Osteomyelitis due to Aspergillus species in chronic granulomatous disease: an update of the literature. Mycoses. 2011;54(6):e686-96.
Vinas FC, King PK, Diaz FG. Spinal aspergillus osteomyelitis. Clin Infect Dis. 1999; 28(6):1223–9.
Studemeister A, Stevens DA. Aspergillus vertebral osteomyelitis in immunocompetent hosts: role of triazole antifungal therapy. Clin Infec Dis. 2011;52(1):e1-6.
Mouas H, Lutsar I, Dupont B, Fain O, Herbrecht R, Lescure FX, Lortholary O; Voriconazole/Bone Invasive Aspergillosis Study Group. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis. 2005;40(8):1141–7.
Kirby A, Hassan I, Burnie J. Recommendations for managing aspergillus osteomyelitis and joint infections based on a review of the literature. J Infect. 2006;52(6):405–14.
Lodge BA, Ashley ED, Steele MP, Perfect JR. Aspergillus fumigatus empyema, arthritis, and calcaneal osteomyelitis in a lung transplant patient successfully treated with posaconazole. J Clin Microbiol. 2004;342(3):1376–8.
Chakrabarti A, Chatterjee S, Radotra BD. Cutaneous and wound aspergillosis. In: Pasqualotto AC (eds). Aspergillosis: from diagnosis to prevention. Springer, Dordrecht, 2009; 939-59.
Ben-Ami R, Lewis RE, Leventakos K, Latgé JP, Kontoyiannis DP. Cutaneous model of invasive aspergillosis. Antimicrob Agents Chemother. 2010;54(1):1848–54.
Hori A, Kami M, Kishi Y, Machida U, Matsumura T, Kashima T. Clinical significance of extra-pulmonary involvement of invasive aspergillosis: A retrospective autopsy-based study of 107 patients. J Hosp Infect. 2002;50(3):175–82.
Jombo GTA, Banwat EB, Gyoh SK. Pulmonary and extra pulmonary manifestations of aspergillosis in clinical practice and potential challenges in management: An analysis of literature review. J Clin Med Res. 2010;2(11):185-93.
Bai QX, Huan Y, Wang JH, Yang LJ, Dong HJ. Successful treatment of liver aspergilloma by caspofungin acetate first-line therapy in a nonimmunocompromised patient. Int J Mol Sci. 2012;13(9):11063-70.
Metta H, Corti M, Redini L, Bruggesser F, Arechavala A, Negroni R, Veliz L. Renal abscess due to Aspergillus fumigatus as the only sign of disseminated aspergillosis in a patient with AIDS. Rev Iberoam Micol. 2010;2783):136-9.
Oosten AW, Sprenger HG, van Leeuwen JT, Meessen NE, van Assen S. Bilateral renal aspergillosis in a patient with AIDS: a case report and review of reported cases. AIDS Patient Care STDS. 2008;22(1):1-6.
Lisson SW, Hellinger WC, Parra RO. Primary bilateral parenchymal renal Aspergillus infection. Urology. 2002;60(2):345.
Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunopharmacology of modern antifungals. Clin Infect Dis. 2008;47(2):226–35.
Roilides E, Lyman CA, Filioti J, Akpogheneta O, Sein T, Lamaignere CG, Petraitiene R, Walsh TJ.et al. Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus. Antimicrob Agents Chemother. 2002;46(6):1974–6.
Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis. 2001;32(5):686-93.
Bellmann R. Pharmacodynamics and pharmacokinetics of antifungals for treatment of invasive aspergillosis. Curr Pharm Des. 2013;19(20):3629-47.
Arnold TM, Dotson E, Sarosi GA, Hage CA. Traditional and emerging antifungal therapies. Proc Am Thorac Soc Vol. 2010;7(3):222-8.
Walsh JT, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M et al. Safety, tolerance, and pharmacocinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother. 2001;45(12):3487-496.
Herbrecht R, Natarajan-Amé S, Nivoix Y, Letscher-Bru V. The lipid formulations of amphotericin B. Expert Opin Pharmacother. 2003;4(8):1277-87.
Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al. Liposomal Amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high–loading dose regimen with standard dosing (AmBiLoad Trial). Clin Infect Dis. 2007; 44(10):1289-97.
Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Time for a new “gold standard”. Clin Infect Dis. 2003;37(3):415-25.
Drew R. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections. Int J Antimicrobial Agents. 2006;27:36-44.
Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doordujin JK, Hop WC et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: A randomized, placebocontrolled trial. Clin Infect Dis. 2008; 46(9):1401-8.
Perfect JR. Aerosolized antifungal prophylaxis: The winds of change? Clin Infect Dis. 2008;46(9):1409-11.
Quindós G, Carrillo-Muñoz AJ, Ruesga MT, AlonsoVargas R, Miranda Y, Tur-Tur C et al. In vitro activity of a new liposomal nystatin formulation against opportunistic fungal pathogens. Eur J Clin Microbiol Infect Dis. 2000;19(8):645-8.
Offner F, Krcmery V, Boogaerts M, Doyen C, Engelhard D, Ribaud P et al; EORTC Invasive Fungal Infections Group. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B. Antimicrob Agents Chemother. 2004; 48(12):4808-12.
Lestner J, Hope WW. Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections. Expert Opin Drug Metab Toxicol. 2013; 9(7):911-26.
Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W, De Beule K. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis. 2001;33(8):e83-90.
Lewis RE. Current concepts in antifungal pharmacology. Symposium on Antimicrobial Therapy Mayo Clin Proc. 2011;86(8):805-17.
Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36(5):630–7.
Lat A, Thompson GR. Update on the optimal use of voriconazole for invasive fungal infections. Infect Drug Resist. 2011;4:43–53.
Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/ pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45(7):649–63.
Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002;46(8):2546–53.
Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs. 2004;64(18):1997-2020.
Maertens J, Marchetti O, Herbrecht R, Cornely OA, Flückiger U, Frere P et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3- 2009 update. Bone Marrow Transplant. 2011;46(5):709-18.
Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG: In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-tohead comparison to voriconazole. J Clin Microbiol. 1999;37(7):2343–5.
Saag MS, Dismukes WE. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother. 1988;32(1):1-8.
Sanati H, Belanger P, Fratti R, Ghannoum M. A new triazole, voriconazole (UK-109,496), blocks sterol. Biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother. 1997;41(11):2492–6.
Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia. 2001;150(3):101–15.
Clancy CJ, Nguyen MH. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis. 1998;17(8):573–5.
Simitsopoulou M, Ioannidis J, Kanellou K, Orfanou A, Walsh TJ, Roilides E. Differential immunomodulatory effects of voriconazole on Toll-like receptors (TLR) 2 and 4 and nuclear factor KB in human monocytes [abstract M737]. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). American Society for Microbiology, 2007:437.
Wang G, Lei HP, Li Z, Tan ZR, Guo D, Fan L et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol. 2009;65(3):281–5.
Brüggemann RJM, Alffenaar JC, Blijlevens NMA, Billaud EM, Kosterink JGW, Verweij PE, Burger DM. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48(10):1441–58.
Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201– 11.
Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol. 2010;69(3):222–30.
Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004;48(6):2166–72.
Pascual A, Nieth V, Calandra T, Bille J, Bolay S, Decosterd LA et al. Variability of voriconazole plasma levels measured by new high performance liquid chromatography and bioassay methods. Antimicrob Agents Chemother. 2007;51(1):137–43.
Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007;109 (8):1532–5.
Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA et al. Improved outcome in central nervous system aspergillosis using voriconazole treatment. Blood. 2005; 106(8):2641-5.
Mousset S, Buchheidt D, Heinz W, Ruhnke M, Cornely OA, Egerer G et al. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2014;93(1):13- 32.
Vehreschild JJ, Böhme A, Buchheidt D, Arenz D, Harnischmacher U, Heussel CP et al. A double-blind trial on prophylactic voriconazole or placebo during induction chemotherapy for acute myelogenous leukaemia. J Infect. 2007;55(5):445-9.
Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004;39(6):797–802.
Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR et al. Blood an marrow transplant clinical trials network. Randomized, doubleblind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116(24):5111-8.
Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006;50(4):1570–2.
Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. 2006;46(2):235–43.
Boyd AE, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW. Adverse reactions to voriconazole. Clin Infect Dis. 2004;39(8):1241–4.
Howard A, Hoffman J, Sheth A. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Ann Pharmacother. 2008;42(12):1859–64.
Herbrecht R. Voriconazole: Therapeutic review of a new azole antifungal. Expert Rev Anti-Infect Ther. 2004;2(4):485–97.
McCarthy KL, Playford EG, Looke DF, Whitby M. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis. 2007;44(5):55–6.
Cowen EW, Nguyen JC, Miller DD, McShane D, Arron ST, Prose NS et al. Chronic Phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol. 2010;62(1):31–7.
Miller DD, Cowen EW, Nguyen JC, McCalmont TH, Fox LP. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol. 2010;146(3):300–4.
Morice C, Acher A, Soufir N, Michel M, Comoz F, Leroy D, Verneuil L. Multifocal aggressive squamous cell carcinomas induced by prolonged voriconazole therapy: a case report. Case Report Med. 2010;2010:351084.
Patterson TF. Treatment of invasive aspergillosis: Polyenes, echinocandins, or azoles? Med Mycol 2006;44:357-62.
Sandherr M, Maschmeyer G. Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis –review of the literature. Eur J Med Res. 2011;16(4):139-44.
Li Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H. Pharmacokinetic/ pharmacodynamic profile of posaconazole. Clin Pharmacokinet. 2010;49(6):379-96.
Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348-59.
Türel O. Newer antifungal agents. Expert Rev Anti Infect Ther. 2011;9(3):325-38.
Natesan SK, Chandrasekar PH. Isavuconazole fort he treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations. Infect Drug Resist. 2016;9:291-300.
Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N et al. Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis. Adv Ther. 2017;34(1):207-20.
Ledoux MP, Toussaint E, Denis J, Herbrecht R. New pharmacological opportunities for the treatment of invasive mould diseases. J Antimicrob Chemother. 2017;72:48–58.
Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A et al. ECIL-6 Guidelines for the treatment of Invasive Candidiasis, Aspergillosis and Mucormycosis in Leukemia and Hematopoietic Stem Cell Transplant Patients. Haematologica. 2017;102(3):433-44.
Nabili M, Shokohi T, Moazeni M, Khodavaisy S, Aliyali M, Badiee P et al. High prevalence of clinical and environmental triazole-resistant Aspergillus fumigatus in Iran: is it a challenging issue? J Med Microbiol. 2016;65(6):468-75.
Viscoli C, Herbrecht R, Akan H, Baila L, Sonet A, Gallamini A et al, Infectious Disease Group of the EORTC: An EORTC phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother. 2009;64(6):1274–81.
Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Ame S, Fohrer C et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis. 2008;47(9):1176–84.
Heinz WJ, Buchheidt D, Ullmann AJ. Clinical evidence for caspofungin monotherapy in the first-line and salvage therapy of invasive Aspergillus infections. Mycoses. 2016;59(8): 480-93.
Wagner C, Graninger W, Presterl E, Joukhadar C. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology. 2006; 78(4):161–77.
Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslaq D, Petersen FB et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39(11):1563– 71.
Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006;53(5):337–49.
Kohno S, Izumikawa K, Yoshida M, Takesue Y, Oka S, Kamei K et al. A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis. Eur J Clin Microbiol Infect Dis. 2013;32(3):387-97.
Kofla G and Ruhnke M. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosisreview of the literatüre. Eur J Med Res. 2011;16(4):159–66.
Gadea I, Mensa J. Potential of anidulafungin in combined therapy (in Spanish). Enferm Infec Microbiol Clin. 2008;26:51–5.
Steinbach WJ, Juvvadi PR, Fortwendel JR, Rogg LE. Newer combination antifungal therapies for invasive aspergillosis. Med Mycol. 2011;49:77-81.
Petraitis V, Petraitiene R, McCarthy MW, Kovanda LL, Zaw MH, Hussain K, Shaikh N, Maung BBW, Sekhon NK, Hope WW, Walsh TJ. Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis. Antimicrob Agents Chemother. 2017;61(9):e00305-17.